Cortexyme Investor Presentation 2021

Cortexyme presents its clinical pipeline focused on atuzaginstat, a gingipain inhibitor for Alzheimer's disease, with pivotal Phase 2/3 GAIN trial data expected in November 2021. The company outlines its disruptive mechanism of action targeting P. gingivalis infection, expanding pipeline including Parkinson's and coronavirus programs, and strong capital position with $153.5M in cash.